Skyrizi

Description

Skyrizi 150 mg/mL is a prescription biologic medicine containing risankizumab-rzaa, an interleukin-23 antagonist used in adults for several approved inflammatory conditions. Official U.S. prescribing information lists uses that include moderate to severe plaque psoriasis, active psoriatic arthritis, moderately to severely active Crohn’s disease, and moderately to severely active ulcerative colitis.

Presented in a convenient 150 mg/mL injection format, Skyrizi 150 mg/mL is a recognized specialist-prescribed treatment option for patients who require targeted biologic therapy. For plaque psoriasis and psoriatic arthritis, official dosing information describes 150 mg by subcutaneous injection at Week 0, Week 4, and every 12 weeks thereafter.

Why Choose Skyrizi 150 mg/mL?

• Trusted Biologic Therapy: Contains risankizumab-rzaa, an FDA-approved biologic treatment.
• 150 mg/mL Strength: Supplied in a standard 150 mg/mL injection format for approved uses.
• Targeted Immune Pathway Support: Works as an IL-23 antagonist in specialist-directed care.
• Convenient Maintenance Dosing: For some approved indications, maintenance dosing is every 12 weeks after starter doses.

Common Usage & Available Strengths

Skyrizi is available in 150 mg/mL for subcutaneous injection for plaque psoriasis and psoriatic arthritis, while other dosage presentations are used in Crohn’s disease and ulcerative colitis treatment pathways. The appropriate product strength, schedule, and administration plan should always follow the recommendation of a licensed healthcare provider and the approved prescribing information.